1. INTRODUCTION {#sec1}
===============

Diabetic retinopathy remains an important cause of visual loss in persons with diabetes. As the prevalence rates of diabetes increase in both the native and nonnative populations, there is increasing concern of the potential increased numbers of patients at risk for diabetic retinopathy. Some potential risk factors for retinopathy include: A1c, BP (systolic and diastolic), and duration of diabetes \[[@B1a]--[@B4]\]. Lipid abnormalities may also play part in the development of retinal changes \[[@B5]\].

It is often assumed that native populations have different prevalence rates of specific vascular complications and of the risk factors that may lead to the development of vascular complications. This paper reviews the prevalence rates of diabetic retinopathy in native and nonnative communities and directly compares the prevalence rates of potential risk factors for the development of diabetic retinopathy in these communities.

2. METHODOLOGY {#sec2}
==============

The Southern Alberta Study of Diabetic Retinopathy (SASDR) was designed to provide assessment of the prevalence and incidence of diabetic retinopathy and other diabetes vascular complications and to assess potential risk factors for the development of retinopathy in a population of subjects with diabetes. Native and nonnative communities were assessed as part of the study. The study was carried out in southern Alberta and included both urban and rural areas and native reserves. At a minimum of three years following the completion of the initial prevalence study, all subjects were invited to take part in the incidence study, which repeated all parameters of the prevalence programme. This paper will review only the prevalence data.

All subjects were identified as either urban (Calgary) or rural, by the postal codes associated to their place of primary residence. Within the borders of the study area, there are six native reserves belonging to Treaty Seven, including the two largest native reserves in Canada, the Blood and Blackfoot reserves. The project was approved by (The Conjoint Health Research Ethics Board, University of Calgary, Canada) and by the medical committees of each of the native reserves. All southern Alberta reserves were represented in the study and are shown in [Table 1](#tab1){ref-type="table"}.

2.1. Recruitment {#subsec2.1}
----------------

Registration centers were established across the study area of southern Alberta. These included all pharmacies, physicians' offices, nursing homes, auxiliary hospitals, native reserves and prisons. Each recruitment site had information and registration packages and staff was individually trained to administer the package to all subjects who used insulin.

The same techniques of registration could not be used for the noninsulin-using subjects as many may not use drugs or have the need to go into a pharmacy. Recruitment of the noninsulin-using subjects began after the identification of the insulin-using subjects. The family physician of each insulin-using subject registered in the study was provided with the number of insulin users registered from their practice and requested to invite the next and subsequent patients with noninsulin-using diabetes within the practice, to register for the study. Each recruitment site that had recruited insulin-using subjects was similarly asked to recruit an equal number of noninsulin-using subjects.

At each of the recruitment sites, if the diabetic subject refused to complete the registration card, the gender, approximate age of the subject, and the specific reason for the refusal was documented.

2.2. Assessment {#subsec2.2}
---------------

Assessment of the individual subjects was undertaken in multiple sites. For those who lived in Calgary, participants attended the central SASDR office at the University of Calgary. For those who could not attend in Calgary, remote sites were set up across southern Alberta. At regular intervals, a mobile van was utilized to carry the staff and retinal and blood sampling equipment to the sites. Subjects were asked to complete an extensive 20-page questionnaire which included a review of ethnic origin, family, and personal medical history with a special emphasis on the history of diabetes, data of diagnosis, drug treatments, and existing vascular complications. A basic examination was performed, including height and weight for calculation of BMI; systolic blood pressure (BP-S) and diastolic blood pressure (BP-D). Each subject was also asked to provide a timed-overnight urine sample and a venous blood sample. Type 2 insulin-using subjects were identified by a serum C-peptide \> 0.05 nmol/L.

Ophthalmology assessmentEach subject had a complete ophthalmology assessment including visual acuity, examination for cataracts, seven-field stereofundus retinal photography, and a slit lamp examination. The photographic slides were coded and forwarded to (Wisconsin Eye Reading Center, Wis, USA) for the classification of the degree of diabetic retinopathy according to the Airlie House classification as adapted by R. Klein et al. \[[@B6]\] [Table 2](#tab2){ref-type="table"}.

A venous blood sample was obtained for the measurement of a nonfasting lipid profile; A1c; serum creatinine; glucose; and serum C-peptide (for assessment of insulin-dependency). The urine sample was assessed for the presence of microalbuminuria and for the presence of ketones. The microalbumin-excretion rate was measured from a timed-overnight urine sample.

To describe the association of ethnicity with retinopathy and potential risk factors, chi-squared tests were used to compare rates and *t*-tests were used to compare means. All testing was done at the 0.05 level of significance.

3. RESULTS {#sec3}
==========

There were a total of 2247 patients with Type 2 diabetes, 232 were native and 2015 were nonnative. [Table 3](#tab3){ref-type="table"} describes the breakdown of patients by ethnicity and retinopathy as follows.

The results of a Chi-Squared test for the equality of the retinopathy rates, (*χ* ^2^ = 0.0005 with 1 degree of freedom, *P* = .98) indicate that ethnicity appears to play no role on the incidence of retinopathy for patients with Type 2 diabetes.

The question of whether ethnicity is related to the degree of retinopathy is described in [Table 4](#tab4){ref-type="table"} as follows.

The Chi-Square test for independence (*χ* ^2^ = 13.52 with 2 degrees of freedom, *P* = .0002) indicates that there is a strong relationship between ethnicity and the degree of retinopathy for patients with Type 2 diabetes. If the patient is native there is a good chance that his/her retinopathy will be more severe than if the patient was nonnative.

[Table 5](#tab5){ref-type="table"} provides a breakdown of these factors relative to native/nonnative classifications as follows.

The native subjects had poorer glucose control with significantly higher levels of A1c compared to the nonnative subjects. There were small but significant differences between native and nonnative subjects in measurements of diastolic blood pressure. Native subjects showed significantly better lipid profiles compared to the nonnative subjects. There were no significant differences in systolic blood pressure measurements or duration of diabetes between the two groups.

Tables [6](#tab6){ref-type="table"}--[9](#tab9){ref-type="table"} investigate the risk factors with degree of retinopathy. Each table is broken down by the risk factor and native/nonnative categories. Ret 1 is no retinopathy; Ret 2 is background retinopathy; Ret 3 is preproliferative retinopathy; and Ret 4 is proliferative retinopathy.

Native subjects had significantly higher A1c values with minor differences in the other parameters [Table 6](#tab6){ref-type="table"}.

Native subjects had significantly higher BP-D; HDL-C values; and shorter duration of diabetes [Table 7](#tab7){ref-type="table"}.

There were no clinically significant differences between the native and nonnative groups apart from significantly higher HDL-C values in native subjects [Table 8](#tab8){ref-type="table"}.

While the mean values in the native group for A1c, blood pressure readings, lipids, and duration are higher than the nonnative groups, there were no significant differences between the two subject groups [Table 9](#tab9){ref-type="table"}.

The most frequent differences in risk factors between native and nonnatives are at the "no retinopathy" stage and the "background" stage. Once a patient has preproliferative or proliferative disease, there is very little or no difference in risk factors regardless of ethnicity.

4. DISCUSSION {#sec4}
=============

The prevalence of diabetes is increasing worldwide. Associated with this increase is an increased risk of development of micro- and macrovascular complications including diabetic retinopathy. Aboriginal or native communities may be at increased risk of developing prediabetes or type 2 diabetes. There may well be an increased risk of microvascular complications amongst these communities \[[@B7]--[@B12]\].

Native communities in north America have previously been identified as having an increased risk of type 2 diabetes \[[@B13]\]. While the risk of developing type 2 diabetes may vary between various native-Canadian nations, many are exhibiting an increased prevalence rate of type 2 diabetes \[[@B12], [@B14]--[@B19]\]. Detailed studies of (Ojibwa-Cree native populations in Sandy Lake, Ontario, Canada) have revealed increased prevalence rates of impaired glucose tolerance as well as type 2 diabetes \[[@B7], [@B9], [@B20]\]. Similar abnormalities have been noted in (James Bay Cree in northern Québec, Canada) \[[@B17]\].

Native Canadians have also been identified as having increased morbidity and mortality associated with diabetes with a greater impact on quality of life and a strong association between diabetes, hypertension, heart disease, and sight impairment \[[@B8]\]. Renal disease is also more prominent with an increased prevalence rate of diabetic end-stage renal disease evident in native Canadians \[[@B22]--[@B24]\].

There are only a limited number of studies related to diabetic retinopathy in native populations. In Canada particularly, many native populations are in remote areas and extensive studies have proven to be difficult. Increased vascular complications, including diabetic retinopathy, have been noted in the James Bay Cree and other native populations \[[@B23a], [@B23b], [@B25], [@B26]\]. Haffner et al. noticed an increase prevalence rate of diabetic retinopathy in Mexican-American diabetic subjects compared to Caucasian diabetic subjects reviewed in (Wisconsin Epidemiologic Study of Diabetes, Wis, USA) suggesting an ethnicity effect on the risk of developing diabetic retinopathy \[[@B27]\]. Studies of the Pima Indians have shown a similar increase in prevalence rates \[[@B28]\]. An urban study, however, carried out in the native population in Vancouver, showed that visual disability was nine times greater than in the general Canadian population but diabetic retinopathy was not a major cause of that visual loss \[[@B29]\].

Various risk factors have been identified as leading to an increased incidence of diabetic retinopathy. These include glycemic control \[[@B3], [@B4], [@B30]--[@B33]\], elevated blood pressure \[[@B2], [@B31], [@B34]--[@B36]\], abnormal lipids \[[@B37], [@B38]\], and duration of diabetes \[[@B39]\]. It is thought that native Canadians may exhibit higher prevalence rates of these risk factors, compared to nonnative individuals. Detailed studies of native-north Americans have revealed high prevalence rates of these risk factors. A review of Sandy Lake community demonstrated high prevalence rates of vascular complications and associated risk factors \[[@B7], [@B10]\]. Studies of other native Canadian communities have revealed similar results \[[@B40], [@B41], [@B42]\].

The prevalence data from the Southern Alberta Study of Diabetic Retinopathy (SASDR) provides a unique opportunity to review prevalence rates of diabetic retinopathy, severity and the potential associated risk factors for the development of retinopathy directly between insulin and noninsulin using type 2 diabetic native and nonnative subjects.

As can be seen from the data presented, there were no differences in prevalence rates of retinopathy between the native and nonnative groups. Native subjects with retinopathy, however, tended to have more advanced changes of retinopathy compared to the nonnative subjects.

When assessing the role of potential risk factors for the development or progression of diabetic retinopathy, again, there were only few and minor differences between native and nonnative subjects. Both native and nonnative subjects with more severe presentation of diabetic retinopathy tended to have higher levels of A1c compared to those with less severe forms of retinopathy. Significantly higher levels of A1c were observed only in native subjects who did not exhibit retinopathy. A1c was not statistically significant for patients with some form of retinopathy. Native subjects tended to have lower total-cholesterol and higher HDL-C values compared to nonnative groups although these differences were small. Duration of diabetes, which is recognized as a major risk factor for the development and severity of diabetic retinopathy, was not significantly different between native and nonnative subjects.

Of interest are the differences in prevalence and severity of diabetic retinopathy in the southern Alberta native subjects compared to those from the detailed Sandy Lake study \[[@B10]\]. The prevalence rates of retinopathy were far higher in the southern Alberta cohort and similar to those identified in the Wisconsin Eye Studies \[[@B43]\].

These data indicate that ethnicity does play a significant role in the development and severity of diabetic retinopathy but potential risk factors that may accelerate the development of retinopathy are not significantly different between native and nonnative groups.
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###### 

Southern Alberta native reserves-treaty seven.

  Reserve       Tribe
  ------------- -----------
  Blood         Blackfoot
  Piikani       Blackfoot
  Blackfoot     Blackfoot
  Morley        Stoney
  Eden Valley   Stoney
  TsuuTina      Sarcee

###### 

Retinal grade classification.

  Grade    Description
  -------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  10--14   no retinopathy
  15--21   microaneurysms or soft exudates or retinal hemorrhages
  31       micro aneurysms with any of: venous loops; soft exudates; intraretinal microvascular abnormalities (IRMA); venous beading; retinal hemorrhages
  41       microaneurysms with any of the following: hemorrhages and 4-5 fields; IRMA 1--3 fields
  51       microaneurysms with one or more of the following: hemorrhages and microaneurysms in 4-5 fields; IRMA in 4 or more fields; venous beading in 2 or more fields
  60       fibrous proliferations
  61       scars of photocoagulation but no evidence of 60 or 65
  65       proliferative retinopathy

###### 

Prevalence of diabetic retinopathy.

                   Native       Nonnative     Total
  ---------------- ------------ ------------- ------------
  No retinopathy   137 (60%)    1208 (60%)    1345 (60%)
  retinopathy      91 (40%)     805 (40%)     895 (40%)
                                              
  Total            228 (100%)   2013 (100%)   2241(100%)

###### 

Degree of retinopathy.

                     Native      Nonnative    Total
  ------------------ ----------- ------------ ------------
  Background         45 (49%)    551 (68%)    596 (67%)
  Preproliferative   33 (36%)    174 (22%)    207 (23%)
  Proliferative      13 (14%)    80 (10%)     93 (10%)
                                              
  Total              91 (100%)   805 (100%)   896 (100%)

###### 

Risk factors for diabetic retinopathy.

  Factor                     Observations   Average   Standard deviation   *P*                      
  -------------------------- -------------- --------- -------------------- -------- ------- ------- ---------
  A1c                        224            2010      7.52                 7.15     2.0     1.78    .008
  BP-S mm/Hg                 228            2010      129                  130      21.59   19.07   .3611
  BP-D mm/Hg                 228            2010      78                   75       10.27   10.11   .0025
  Total-Cholesterol mmol/L   225            2011      5.4311               5.5454   1.12    1.32    .0274
  HDL-C mmol/L               225            2007      1.1748               1.056    0.37    0.32    \<.0005
  Duration years             221            1981      8.26                 9.08     7.13    8.42    .164

###### 

No retinopathy and associated risk factors.

  Ret1                       Observations   Average   Standard deviation   *P*                     
  -------------------------- -------------- --------- -------------------- ------- ------- ------- -------
  A1c                        134            1205      7.20                 6.85    1.89    1.67    .0455
  BP-S mm/Hg                 137            1205      125                  127     18.3    17.8    .1262
  BP-D mm/Hg                 137            1205      77                   75      9.2     10      .0544
  Total-Cholesterol mmol/L   135            1206      5.323                5.533   1.02    1.32    .0733
  HDL-C mmol/L               135            1202      1.182                1.055   0.385   0.312   .003
  Duration years             133            1190      5.962                7.086   5.95    7.65    .1015

###### 

Background retinopathy and associated risk factors.

  Ret2                       Observations   Average   Standard deviation   *P*                      
  -------------------------- -------------- --------- -------------------- -------- ------- ------- -------
  A1c                        45             551       7.74                 7.37     1.77    1.67    .1596
  BP-S mm/Hg                 45             551       131                  133      20.5    19.9    .662
  BP-D mm/Hg                 45             551       80                   76       11.3    9.9     .01
  Total-Cholesterol mmol/L   45             551       5.282                5.513    1.01    1.26    .2291
  HDL-C mmol/L               45             551       1.178                1.076    0.391   0.335   .0524
  Duration years             40             535       8.6                  11.215   5.56    8.51    .0564

###### 

Preproliferative retinopathy and associated risk factors.

  Ret3                       Observations   Average   Standard deviation   *P*                      
  -------------------------- -------------- --------- -------------------- -------- ------- ------- -------
  A1c                        33             174       8.03                 8.17     2.0     1.89    .7006
  BP-S mm/Hg                 33             174       77                   77       11.4    10.1    .965
  BP-D mm/Hg                 33             174       133                  137      26.3    20.6    .4216
  Total-Cholesterol mmol/L   33             174       5.376                5.731    1.6     1.53    .2254
  HDL-C mmol/L               33             174       1.166                1.022    0.302   0.297   .0119
  Duration years             33             174       13.939               13.362   6.99    8.24    .7064

###### 

Proliferative retinopathy and associated risk factors.

  Ret4                       Observations   Average   Standard deviation   *P*                     
  -------------------------- -------------- --------- -------------------- ------- ------- ------- -------
  A1c                        12             80        8.76                 7.88    2.55    1.55    .2596
  BP-S mm/Hg                 13             80        147                  136     32.4    20.7    .2577
  BP-D mm/Hg                 13             80        80                   76      13.8    12.7    .2593
  Total-Cholesterol mmol/L   12             80        5.7108               5.546   1.17    1.31    .6828
  HDL-C mmol/L               12             80        1.113                1.01    0.338   0.249   .208
  Duration years             13             80        16.769               15.4    9.2     9.25    .6217
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